Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 4 |
List of Tables | 5 | 1 |
List of Figures | 5 | 1 |
Introduction | 6 | 1 |
Global Markets Direct Report Coverage | 6 | 1 |
Yellow Fever Overview | 7 | 1 |
Therapeutics Development | 8 | 2 |
Pipeline Products for Yellow Fever Overview | 8 | 1 |
Pipeline Products for Yellow Fever Comparative Analysis | 9 | 1 |
Yellow Fever Therapeutics under Development by Companies | 10 | 1 |
Yellow Fever Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
Yellow Fever Pipeline Products Glance | 12 | 2 |
Clinical Stage Products | 12 | 1 |
Early Stage Products | 13 | 1 |
Yellow Fever Products under Development by Companies | 14 | 1 |
Yellow Fever Products under Investigation by Universities/Institutes | 15 | 1 |
Yellow Fever Companies Involved in Therapeutics Development | 16 | 10 |
Arno Therapeutics, Inc. | 16 | 1 |
Bavarian Nordic A/S | 17 | 1 |
BioCryst Pharmaceuticals, Inc. | 18 | 1 |
Ennaid Therapeutics, LLC | 19 | 1 |
iBio, Inc. | 20 | 1 |
Johnson &Johnson | 21 | 1 |
NewLink Genetics Corporation | 22 | 1 |
Panacea Biotec Limited | 23 | 1 |
Sihuan Pharmaceutical Holdings Group Ltd. | 24 | 1 |
Valneva SE | 25 | 1 |
Yellow Fever Therapeutics Assessment | 26 | 10 |
Assessment by Monotherapy Products | 26 | 1 |
Assessment by Combination Products | 27 | 1 |
Assessment by Target | 28 | 2 |
Assessment by Mechanism of Action | 30 | 2 |
Assessment by Route of Administration | 32 | 2 |
Assessment by Molecule Type | 34 | 2 |
Drug Profiles | 36 | 25 |
(arenavirus + yellow fever) vaccine Drug Profile | 36 | 1 |
AR-12 Drug Profile | 37 | 3 |
BCX-4430 Drug Profile | 40 | 3 |
DEF-201 Drug Profile | 43 | 2 |
FDX-000 Drug Profile | 45 | 1 |
JK-05 Drug Profile | 46 | 1 |
RKP-00156 Drug Profile | 47 | 1 |
Small Molecule to Inhibit NS4B for Dengue and Yellow Fever Virus Infections Drug Profile | 48 | 1 |
Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections Drug Profile | 49 | 1 |
Synthetic Peptides for Yellow Fever Drug Profile | 50 | 1 |
XRX-001 Drug Profile | 51 | 1 |
yellow fever [strain YF17D] vaccine Drug Profile | 52 | 1 |
yellow fever vaccine Drug Profile | 53 | 1 |
yellow fever vaccine Drug Profile | 54 | 1 |
yellow fever vaccine Drug Profile | 55 | 1 |
yellow fever vaccine Drug Profile | 56 | 1 |
yellow fever vaccine Drug Profile | 57 | 1 |
yellow fever vaccine Drug Profile | 58 | 1 |
yellow fever vaccine Drug Profile | 59 | 1 |
yellow fever vaccine Drug Profile | 60 | 1 |
Yellow Fever Dormant Projects | 61 | 1 |
Yellow Fever Product Development Milestones | 62 | 3 |
Featured News &Press Releases | 62 | 1 |
Jul 27, 2016: Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine | 62 | 1 |
Jul 27, 2016: NIH launches early-stage yellow fever vaccine trial | 62 | 1 |
Apr 07, 2011: Xcellerex Announces Positive Results From Phase I Clinical Trial Of XRX-001 | 63 | 2 |
Appendix | 65 | 2 |
Methodology | 65 | 1 |
Coverage | 65 | 1 |
Secondary Research | 65 | 1 |
Primary Research | 65 | 1 |
Expert Panel Validation | 65 | 1 |
Contact Us | 65 | 1 |
Disclaimer | 66 | 1 |